An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo

Bibliographic Details
Title: An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
Authors: Nian E. Zhou, Su Tang, Xuelin Bian, Maloy K. Parai, Inna V. Krieger, Armando Flores, Pradeep K. Jaiswal, Radha Bam, Jeremy L. Wood, Zhe Shi, Laura J. Stevens, Trevor Scobey, Meghan V. Diefenbacher, Fernando R. Moreira, Thomas J. Baric, Arjun Acharya, Joonyoung Shin, Manish M. Rathi, Karen C. Wolff, Laura Riva, Malina A. Bakowski, Case W. McNamara, Nicholas J. Catanzaro, Rachel L. Graham, David C. Schultz, Sara Cherry, Yoshihiro Kawaoka, Peter J. Halfmann, Ralph S. Baric, Mark R. Denison, Timothy P. Sheahan, James C. Sacchettini
Source: Cell Reports, Vol 43, Iss 11, Pp 114929- (2024)
Publisher Information: Elsevier, 2024.
Publication Year: 2024
Collection: LCC:Biology (General)
Subject Terms: CP: Microbiology, Biology (General), QH301-705.5
More Details: Summary: Safe, effective, and low-cost oral antiviral therapies are needed to treat those at high risk for developing severe COVID-19. To that end, we performed a high-throughput screen to identify non-peptidic, non-covalent inhibitors of the SARS-CoV-2 main protease (Mpro), an essential enzyme in viral replication. NZ-804 was developed from a screening hit through iterative rounds of structure-guided medicinal chemistry. NZ-804 potently inhibits SARS-CoV-2 Mpro (0.009 μM IC50) as well as SARS-CoV-2 replication in human lung cell lines (0.008 μM EC50) and primary human airway epithelial cell cultures. Antiviral activity is maintained against distantly related sarbecoviruses and endemic human CoV OC43. In SARS-CoV-2 mouse and hamster disease models, NZ-804 therapy given once or twice daily significantly diminished SARS-CoV-2 replication and pathogenesis. NZ-804 synthesis is low cost and uncomplicated, simplifying global production and access. These data support the exploration of NZ-804 as a therapy for COVID-19 and future emerging sarbecovirus infections.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2211-1247
Relation: http://www.sciencedirect.com/science/article/pii/S2211124724012804; https://doaj.org/toc/2211-1247
DOI: 10.1016/j.celrep.2024.114929
Access URL: https://doaj.org/article/fee5e4e3bedd475abadbb75db127898b
Accession Number: edsdoj.fee5e4e3bedd475abadbb75db127898b
Database: Directory of Open Access Journals
More Details
ISSN:22111247
DOI:10.1016/j.celrep.2024.114929
Published in:Cell Reports
Language:English